QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
QIAGEN Expands Tuberculosis Portfolio With New NGS Panel To Support Real-Time Surveillance And Combat Antimicrobial Resistance
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world's leading infectious disease killer.
QIAGEN（紐約證券交易所代碼：QGEN，法蘭克福主要標準：QIA））））今天宣佈推出供研究使用的QiaseQ xHYB結核分枝桿菌試劑盒，這是對抗結核病（TB）的新工具，結核病是世界領先的傳染病殺手。
Building on QIAGEN's ongoing efforts to support global TB management and control, which include the leading diagnostics test QuantiFERON-TB Gold Plus, the new panel enables culture-free whole genome sequencing (WGS) directly from samples such as sputum or cerebrospinal fluid. This innovation significantly reduces the time to result and enables real-time epidemiology of TB outbreaks, addressing a critical need in the field of TB surveillance and control.
在QIAGEN持續努力支持全球結核病管理和控制（包括領先的診斷測試Quantiferon-TB Gold Plus）的基礎上，新試劑盒支持直接從痰液或腦脊液等樣本中進行無培養全基因組測序（WGS）。這項創新顯著縮短了得出結果的時間，實現了結核病疫情的實時流行病學，滿足了結核病監測和控制領域的關鍵需求。
The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS). It is designed against the seven major lineages of TB, covering the full breadth of diversity. By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
QiaseQ xHYB 結核分枝桿菌試劑盒代表了在使用下一代測序 (NGS) 從複雜宿主樣本中解決細菌 WGS 問題方面取得的重大進展。它針對結核病的七個主要譜系而設計，涵蓋了所有多樣性。通過無需進行4至6周的細菌培養，該小組顯著加快了獲得結果的過程。
"The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance," said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN. "This innovative panel not only streamlines the workflow for healthcare professionals and researchers but also enables the real-time tracking of TB outbreaks, a crucial aspect in combating the spread of this devastating disease and managing the growing threat of drug-resistant TB."
QIAGEN副總裁兼生命科學業務領域負責人Nitin Sood表示：“QiaseQ xHYB結核分枝桿菌小組的推出反映了我們對應對結核病和抗微生物藥物耐藥性等全球健康挑戰的持續承諾。“這個創新的面板不僅簡化了醫療保健專業人員和研究人員的工作流程，而且可以實時跟蹤結核病疫情，這是抗擊這種毀滅性疾病傳播和管理日益增長的耐藥結核病威脅的關鍵方面。”
"Innovative aspects of this workflow are the whole genome analysis from clinical samples, avoidance of the culturing delay, and inclusion of genetic diversity," stated Daniela Maria Cirillo, MD, PhD, Head of Emerging Bacterial Pathogens Unit at IRCCS San Raffaele Scientific Institute, Milan, Italy.
意大利米蘭IRCCS聖拉斐爾科學研究所新興細菌病原體部門負責人丹妮拉·瑪麗亞·西里洛醫學博士說：“該工作流程的創新方面是對臨床樣本進行全基因組分析，避免培養延遲，以及納入遺傳多樣性。”
The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment. The panel covers all AMR-related genes, allowing for the identification of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB), which is caused by bacteria that do not respond to the most effective first-line TB drugs.
QiaseQ xHYB結核分枝桿菌小組在抗微生物藥物耐藥性（AMR）的檢測和管理中也發揮着至關重要的作用，抗微生物藥物耐藥性（AMR）是結核病治療中日益受到關注的問題。該小組涵蓋了所有抗微生物耐藥性相關基因，從而可以鑑定出耐藥結核菌株，包括耐多藥結核（MDR-TB），耐多藥結核病是由對最有效的一線結核藥物無反應的細菌引起的。
譯文內容由第三人軟體翻譯。